E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 5/23/2016 in the Prospect News Structured Products Daily.

New Issue: Credit Suisse prices $1.82 million contingent coupon autocallables on pharma stocks

By Wendy Van Sickle

Columbus, Ohio, May 23 – Credit Suisse AG, London Branch priced $1.82 million of contingent coupon autocallable yield notes due May 24, 2018 linked to the common stocks of Celgene Corp., Gilead Sciences, Inc. and Regeneron Pharmaceuticals, Inc., according to a 424B2 filing with the Securities and Exchange Commission.

The notes will pay a quarterly coupon at an annual rate of 22.6% if each stock closes at or above 70% of its initial level on the observation date for that quarter.

The notes will be called at par if each stock closes at or above its initial level on any quarterly observation date on or after Aug. 19, 2016.

The payout at maturity will be par unless any stock closes at or below its knock-in level, 70% of its initial level, in which case the payout will be the number of shares of the lowest performing stock equal to the physical delivery amount, plus a cash amount in respect of any fractional share.

Credit Suisse Securities (USA) LLC is the agent.

Issuer:Credit Suisse AG, London Branch
Issue:Contingent coupon autocallable yield notes
Underlying stocks:Celgene Corp., Gilead Sciences, Inc. and Regeneron Pharmaceuticals, Inc.
Amount:$1.82 million
Maturity:May 24, 2018
Coupon:Each quarter, notes pay contingent coupon at rate of 22.6% per year unless any stock closes below barrier level on observation date for that quarter
Price:Par
Payout at maturity:Par unless any stock finishes below knock-in level, in which case number of shares of lowest performing stock equal to the physical delivery amount
Call:Beginning Aug. 19, automatically at par if each stock closes at or above initial share price on any quarterly observation date
Initial share prices:$99.94 for Celgene, $82.14 for Gilead and $383.30 for Regeneron
Barrier level:$69.958 for Celgene, $57.498 for Gilead and $268.31 for Regeneron; 70% of initial share prices
Pricing date:May 19
Settlement date:May 26
Agent:Credit Suisse Securities (USA) LLC
Fees:3%
Cusip:22548Q6U4

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.